Phase 3 Data Show TONMYA Beats Placebo on Pain and FIQR at Week 14
TNXP is trading near its 52-week low of $5.01 (7.0% above the low).
Summary
Two Phase 3 trials, RELIEF and RESILIENT, show TONMYA improved pain and FIQR symptom and function scores versus placebo at Week 14. RESILIENT hit statistical significance at p≤0.001; RELIEF was only nominally significant, so the strength of the claim rests on the stronger trial. No new safety signals appeared, which lowers the risk of label changes. The data are post-approval reinforcement for a drug already launching in the U.S. since November 2025, so the near-term value is in prescriber conversion and payer coverage rather than a new approval. This lands after the October 15 8-K pre-announcing Q3 TONMYA revenue of $14-15 million and about $162.8 million in cash, and after Dr. Reddy's Paragraph IV ANDA challenge to TONMYA patents filed October 2 — the efficacy package helps the commercial and patent-defense story but does not resolve the litigation.
At the time of this announcement, TNXP was trading at $5.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $90.9M. The 52-week trading range was $5.01 to $20.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.